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Background: Most of Multiple Sclerosis (MS) patients undergo disease modifying drug (DMD) therapy at
childbearing age. The objective of this prospective, collaborative study, was to assess outcomes of pregnancies
fathered by MS patients undergoing DMD.
Methods: Structured interviews on pregnancies fathered by MS patients gathered in the Italian Pregnancy Dataset
were collected; pregnancies were divided according to father exposure or unexposure to DMD at time of
procreation. Treatment were compared with multivariable logistic and linear models.
Results: Seventy-eight pregnancies fathered by MS patients were tracked. Forty-five patients were taking DMD at
time of conception (39 beta-interferons, 6 glatiramer acetate), while 33 pregnancies were unexposed to DMD.
Seventy-five pregnancies ended in live-births, 44 in the exposed and 31 in the unexposed group. No significant
differences between the two groups were found in the risk of spontaneous abortion or malformations (p > 0.454),
mean gestational age (p = 0.513), frequency of cesarean delivery (p = 0.644), birth weight (p = 0.821) and birth
length (p = 0.649). In comparison with data of the Italian general population, the proportion of spontaneous
abortion and caesarean delivery in exposed pregnancies fell within the estimates, while the proportion of pre-term
delivery in the exposed group was higher than expected.
Conclusions: Our data indicate no association between paternal DMD exposure at time of conception and risk of
spontaneous abortion, adverse fetal outcomes and congenital malformations. Further studies clarifying the role of
DMD fathers intake prior and during pregnancy are desirable, to supply guidelines for clinical practice.
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Multiple Sclerosis (MS) is the most frequent and import-
ant inflammatory demyelinating disease of the Central
Nervous System (CNS) [1]. Since the disease mostly af-
fects young people at childbearing age, great interest ex-
ists about the effects on pregnancy outcomes and health
of the baby related with disease modifying drugs (DMD)* Correspondence: mariapia.amato@unifi.it
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unless otherwise stated.taken around conception and during pregnancy. Over
the past few years, a number of papers have addressed
issues of safety of the DMDs at the time of procreation
and during pregnancy in MS mothers [2]. In particular,
prospective cohort studies observed no major adverse
safety signals associated with Interferon-beta (IFN-beta)
exposure, compared with outcomes of unexposed preg-
nancies in MS patients [3,4]. In a previous collaborative
Italian study [3] exposure to IFN-beta during pregnancy
was associated with lower mean birth weight, shorter
mean birth length of the baby and shorter pregnancytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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without any major impact on children health. Despite
limited sample size, studies on Glatiramer Acetate (GA)
exposure also reported no strong safety signals, with the
main fetal and pregnancy outcomes being comparable to
those observed in the general population [5].
On the other hand, there is a dearth of information on
the role of paternal DMD therapy on pregnancy outcome.
Potential mechanisms of adverse effects may be due to
direct mutagenic actions, impairment of spermatogenesis,
or the transfer of chemicals via semen [6]. Expression of
IFN receptors has been reported in the sperm cell [7] and
cytokines and IFNs can have direct effects on spermato-
genic cell differentiation and spermatogenesis [8]. More-
over, IFN-alfa has been found to impair spermatogenesis
in a pre-clinical study [9]. As for the role of paternal
DMD exposure in MS, a previous study [10] showed that
MS-fathers taking DMD had new-borns with higher birth
weight in comparison with children of MS-mothers (ex-
posed or not to IFN-beta). Moreover, birth weight was
only slightly lower in children of MS-fathers compared to
a collective of healthy women [10]. On the basis of these
findings, the authors concluded that MS-fathers’ DMD
therapy is not associated with major risks on procreation.
The study, however, was conducted in a small sample (32
males) and did not report a comparison with pregnancy
outcomes in MS-fathers not exposed to DMD. A recently
published study [11] addressed the association between
DMD exposure and birth outcomes in 195 newborns of
exposed and unexposed MS fathers. The authors found
no compelling evidence to suggest that exposure was
associated with either lower birth weight or gestational
age [11].
The MS Study Group of the Italian Neurological Society
launched a project on pregnancy in MS, establishing a
network among the main national MS Centers. The
dataset collected included information on pregnancy out-
comes mothered and fathered by MS patients.
In this prospective, collaborative study, we focused on
pregnancy and fetal outcomes related to MS patients who
had fathered offspring while being treated with DMD.
Methods
The Italian Pregnancy dataset has been described in detail
elsewhere [3]. In brief, all pregnancies mothered and fa-
thered by MS patients, diagnosed according to McDonald’s
criteria [12] and referring to the participating Centers be-
tween 2002 and 2008 were identified and tracked over the
whole gestational period. The 21 participating Italian MS
Centers are located throughout the entire country; in
each center patients were regularly followed-up every
six months and in case of relapses. Demographic, clin-
ical and therapeutic data were gathered by means of a
standardized information form. Within six months afterthe end of pregnancy (delivery, miscarriage or abortion),
patients were administered a semi-structured interview,
dealing with pregnancy outcomes and potential con-
founders; children follow-up data were gathered after
delivery and over a mean two-year period, considering
that most malformations are usually identified during
the first months of life.
The information form included a section related to MS
patients (demographic data, education, smoke, alcohol in-
take, family history of malformations or other diseases,
data regarding MS history and therapy), a section related
to their partners’ pregnancy (maternal pharmacological
therapies, in utero exposure to toxins or radiations, folic
acid supplementation, maternal smoke, alcohol intake,
abortion, pregnancy complications, amniocentesis, eco-
graphic alterations), delivery and fetal outcomes (weeks of
gestation, cesarean delivery, epidural anesthesia, neonatal
complications, sex of the baby, birth weight and length,
Apgar index at fifth minute, malformations). Conception
was determined as 14 days after the mother’s last men-
strual period. A specific section of the questionnaire inves-
tigated major developmental problems and malformations
of the babies detected following birth, gathered and up-
dated after delivery. In case of any malformation or major
developmental problems were identified from the ques-
tionnaire, the baby’s clinical charts were reviewed.
Pregnancies were divided into two groups: those fa-
thered by MS patients taking DMD at time of procre-
ation or who had discontinued DMD within 70 days
from conception (exposed pregnancies) and those fa-
thered by MS patients who were not taking any medica-
tion, i.e. who had discontinued DMD at least 70 days
from conception or who had never been treated (unex-
posed pregnancies).
Data on spontaneous abortion (before 22 completed
weeks of gestation), pre-term delivery (before 37 weeks
of gestation), cesarean delivery, baby birth weight and
length were compared between DMD exposed and unex-
posed pregnancies; furthermore, the proportions of spon-
taneous abortion, pre-term and cesarean delivery were
compared with data reported in the Italian population
[13], derived from the Italian Statistical Institute (ISTAT)
in 2005.
The study was approved by the Ethic Committee of
the University of Florence and a written informed con-
sent was obtained from all patients.
Statistical analysis
Outcomes considered in statistical analysis were spon-
taneous abortion (yes vs no), pre-term delivery (yes vs
no), cesarean delivery (yes vs no), birth weight and
length of babies.
Baseline characteristics for treatment groups were re-
ported as frequency (percentage) and mean ± standard
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exact χ2 and Mann–Whitney U tests when appropriate.
Multivariable logistic and linear models were used for
treatment comparisons, including as confounders factors
related to MS fathers (including age at conception, educa-
tion as an indicator of the socioeconomic status, disease
duration), factors related to mothers (previous pregnancies
and abortions [yes vs. no]), factors collected for both the
father and the mother (smoking, alcohol and substance
exposure during pregnancy [yes vs. no]), and factors related
to delivery and fetal outcomes (gestational age, cesarean de-
livery, gender of the baby). In particular, a) the multivariable
logistic model assessing spontaneous abortion as dependent
variable included as confounders: age at conception, educa-
tion, disease duration, previous pregnancies and abortions
(yes vs. no), smoking, alcohol and substance exposure dur-
ing pregnancy (yes vs. no). b) The multivariable logistic
model assessing pre-term delivery as dependent variable in-
cluded as confounders: age at conception, education, dis-
ease duration, previous pregnancies and abortions (yes vs.
no), smoking, alcohol and substance exposure during preg-
nancy (yes vs. no), cesarean delivery, gender of the baby. c)
The multivariable logistic model assessing caesarean de-
livery as dependent variable included as confounders:
age at conception, education, disease duration, previous
pregnancies and abortions (yes vs. no), smoking, alcohol
and substance exposure during pregnancy (yes vs. no),
gestational age, cesarean delivery, gender of the baby. d)
The multivariable linear model assessing birth-weight as
dependent variable included as confounders: age at con-
ception, education, disease duration, previous pregnan-
cies and abortions (yes vs. no), smoking, alcohol and
substance exposure during pregnancy (yes vs. no), gesta-
tional age, cesarean delivery, gender of the baby. e) The
multivariable linear model assessing birth-length as
dependent variable included as confounders: age at con-
ception, education, disease duration, previous pregnan-
cies and abortions (yes vs. no), smoking, alcohol and
substance exposure during pregnancy (yes vs. no), gesta-
tional age, cesarean delivery, gender of the baby.
Education missing data were substituted with the mean
value of the study sample. Other missing data were de-
leted from the analysis.
Comparisons with Italian population data of proportions
of spontaneous abortion, pre-term and cesarean delivery
were performed using a one-sample binomial test with a
95% CI.
We used the SPSS 20.0 running on Windows (SPSS
Chicago, IL, USA).
Results
Study sample
During the study period, a total of 78 pregnancies
fathered by MS patients were tracked (Figure 1; Table 1).The median follow-up period after delivery was 1.8 years
(range 0.1-10.7 years).
Forty-five patients (57.7%) were taking DMD around
the time of conception (17 subcutaneous interferon Beta-
1a (IFNB-1a), 14 intramuscular IFNB-1a, 8 subcutaneous
IFNB-1b, 6 glatiramer acetate (GA) (Table 1).
The group of 33 unexposed pregnancies included those
fathered by MS patients who had never been treated with
DMD (27 subjects) or had interrupted DMD intake at
least 70 days before conception (within six months in six
subjects).
Twenty-six patients were classified as smokers, 14 in
the exposed and 12 in the unexposed group. Further-
more, 14 patients were customary alcohol consumers, 10
in the exposed and 4 in the unexposed group.
In pregnant partners of patients’ group there were five
smokers, two in the exposed and three in the unexposed
pregnancy group, while no women reported either alco-
hol intake or drug and toxin exposure during pregnancy.
Five women had had previous pregnancies (two exposed,
three unexposed) and two had had previous abortions
(one exposed, one unexposed).Abortion and fetal malformations
A total of 78 pregnancies were analyzed: 45 exposed and
33 unexposed. We observed 75 pregnancies resulting in
live-births (36 males, 39 females), 44 in the exposed and
31 in the unexposed pregnancy group. One pregnancy of
the exposed group ended in spontaneous abortion, occur-
ring after approximately 12 weeks of gestation (Figure 1).
Three (6.7%) fetal malformations or complications
were observed in the exposed group (scalp hemangioma,
esophageal atresia, jaundice and hip dysplasia), while
four (12.1%) occurred in the unexposed group: Edward
Syndrome, Down Syndrome, both leading to intentional
therapeutic abortion, one case of ocular malformation
(myopia and cataract) and one of renal agenesis (solitary
kidney) (Table 2).
There was no significant association between DMD
father exposure and risk of spontaneous abortion or mal-
formations (Fisher’s exact χ2 test p > 0.454).Pre-term and cesarean delivery
Mean gestational age was 39.0 ± 2.1 weeks in exposed
pregnancies and 38.7 ± 5.2 in the unexposed ones (p =
0.513). Pre-term delivery was observed in seven exposed
pregnancies (17.1% of live birth deliveries) and three
unexposed pregnancies (9.7% of live birth deliveries;
p = 0.499). Pre-term delivery was observed at 32 and at
33 weeks in two cases, at 36 weeks for two babies and at
37 weeks for three babies in exposed pregnancies. The
three preterm unexposed pregnancies ended at 35, 36
and 37 weeks respectively.
* due to major malformations (Edward Syndrome, Down Syndrome)
78 MS fathers
78 pregnancies
Exposed to DMD
45 men
Not Exposed
33 men
44 Live births
1 Spontaneous abortion
31 Live births
2 intentional therapeutic 
abortions*
Figure 1 Flow-chart of the pregnancies enrolled in the study.
Table 1 Characteristics of the study sample
Total sample (#78) Exposed to DMD (#45) Not-exposed (#33) p
Variables related to MS father
Age, mean (SD) years (#78) 34.8 (4.8) 35.4 (5.3) 33.9 (3.9) 0.476*
Education, mean (SD) years (#62) 13.4 (3.5) 13.2 (3.3) 13.8 (4.0) 0.548*
Age at onset, mean (SD) years (#75) 26.5(6.8) 27.0 (7.2) 25.7 (6.2) 0.352*
Disease duration, mean (SD) years (#74) 8.4 (5.9) 8.5 (6.0) 8.3 (5.9) 0.812*
Smokers # (%) (#78) 26 (33.3) 14 (31.1) 12 (36.4) 0.627**
Alcohol # (%) (#78) 14 (17.9) 10 (22.2) 4 (12.1) 0.251**
Variables related to pregnancy and fetal outcomes
Drug and toxin exposure # (%) (78) - - - -
Smoking exposure # (%) (78) 5 (6.4) 2 (4.4) 3 (9.1) 0.645§
Alcohol exposure # (%) (#78) - - - -
Gestational age (weeks) (#72) 38.9 (3.8) 39.0 (2.1) 38.7 (5.2) 0.513*
Preterm delivery # (%) (#72) 10 (13.9) 7 (17.1) 3 (9.7) 0.499§
Caesarean delivery # (%) (#75) 24 (32.0) 15 (34.1) 9 (29.0) 0.644**
Epidural analgesia # (%) (#75) 16 (21.3) 10 (22.7) 6 (19.4) 0.726**
Gender of the baby male/female (#75) 36/39 21/23 15/16 0.955**
Birth-weight mean (SD) gr (#75) 3301.3 (454.9) 3282.3 (445.5) 3328.4 (474.1) 0.821*
Birth-length mean (SD) cm (#67) 50.1 (2.2) 49.9 (2.3) 50.2 (2.1) 0.649*
DMD: Disease Modifying Drug; SD: Standard Deviation.
*Mann Whitney U-test; ** χ2 test; §Fisher’s exact χ2 test.
p values related to the exposed versus unexposed group comparison.
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Table 2 Fetal malformations/complications
Exposed pregnancies Unexposed pregnancies
Fetal malformation/
complications
(p = 0.454)*
1 Scalp hemangioma 1 Edward Syndrome
1 Esophageal atresia 1 Down Syndrome
1 Jaundice and hip
dysplasia
1 Ocular malformation
(myopia and cataract)
1 Renal agenesis (solitary
kidney)
*Fisher’s exact χ2 test.
Table 4 Maternal complications in pregnancies where the
father was exposed or unexposed to a DMD for MS at the
time of conception
Exposed pregnancies Unexposed
pregnancies
Maternal complications
(p = 0.130)
2 Pre-eclampsia/eclampsia 1 Placental
abruption
2 Threatened abortion
1 Threatened preterm
delivery
1 Partial placental abruption
1 Minor infection
*Fisher’s exact χ2 test.
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95% CI 1.00-20.50; p = 0.050) was the only predictor of
pre-term delivery.
Cesarean delivery was performed in 15 exposed (34.1%
of live birth deliveries) and 9 unexposed pregnancies
(29.0% of live birth delivery; p = 0.644) and was associ-
ated with lower gestational age (OR = 0.74; 95% CI 0.55-
0.99; p = 0.040) in multivariable analysis.
Birth weight and length
Mean birth-weight of newborns was 3.282 ± 445 g in
exposed and 3.328 ± 474 g in unexposed pregnancies
(p = 0.821).
Mean birth-length was 49.9 ± 2.3 cm in the exposed
and 50.2 ± 2.1 cm in the unexposed group (p = 0.649).
In multivariable analysis, father’s higher education
(school years) and lower age at conception were associ-
ated with lower birth-weight (Table 3). Higher educa-
tion predicted shorter birth-length (Table 3).
Pregnancy complications and follow up of the babies
Maternal complications occurred in seven out of 44
live birth pregnancies in the exposed group (15.9%) and
in one out of 31 live birth pregnancies (3.2%) in the
unexposed group (p = 0.130; Table 4). In the exposed
group, we observed two cases of preeclampsia, one par-
tial placental abruption, two threatened abortion, one
threatened preterm delivery and a minor infection,Table 3 Significant predictors of birth-weight and
birth-length in live birth pregnancies
B p
Birth-weight
Education* −35.1 0.048
Age at conception* 22.4 0.038
Birth-length
Education* −0.25 0.004
Multivariable linear regression models including as confounders: age at
conception, education, disease duration, previous pregnancies and abortions
(yes vs. no), smoking, alcohol and substance exposure during pregnancy
(yes vs. no), gestational age, cesarean delivery, gender of the baby.
*related to the father.while in the unexposed group we found one case of
placental abruption.
In a median follow-up period of 1.8 years (range 0.1-
10.7), we observed one developmental abnormality (mild
speech disorder) in a child of the unexposed group.
Comparison between exposed pregnancies and Italian
general population data
During the year 2005, in the Italian population, a total of
128.09 spontaneous abortions every 1,000 live-births were
observed [13]. Hypothesizing the same incidence in our
cohort, the 95% CI expected proportion of spontaneous
abortions in the exposed group was 1.5%–20.5%. In our
sample the observed proportion of spontaneous abortion
was one in 44 live-births, which fell within the estimates.
Pre-term delivery was observed in 6.7% of live births
and caesarean delivery in 37.3% [13]. Hypothesizing the
same incidence, the 95% CI expected proportion of pre-
term delivery in the exposed group was 0%–14.3%, and
the 95% CI expected proportion of caesarean delivery
was 22.7%-51.9%. The proportion of pre-term delivery
observed in the exposed group (17.1%) was higher than
expected, whereas the proportion of caesarean delivery
(34.1%) fell within the estimates.
Discussion
Increasing interest has been posed on MS patients parent-
hood, and in particular on DMD exposure around concep-
tion and early pregnancy [14]. Previous studies have not
reported any major adverse safety signals associated with
the mothers exposure to interferon beta or glatiramer
acetate on risk of obstetric/neonatal complications and
congenital malformations [3-5], although some studies
have suggested potential harm of interferon beta in
terms of lower mean birth weight and length and pre-
term birth [2].
The information on pregnancy and fetal outcomes of
MS-fathers is limited. In a recent study, paternal MS and
MS-related clinical factors were not significantly associated
with birth outcomes [15]. As for MS-fathers’ exposure to
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tients under DMD no major adverse safety signals were
found [10,11]. No differences in the risk of spontaneous
abortion and congenital anomalies, birth weights and birth
lengths was observed between father-exposed pregnancies
and data obtained from the general population; paternity
of MS-fathers under DMD resulted in only slightly lower
birth weight compared to a collective of healthy women
[10]. This finding was not confirmed in a recent study on a
larger sample, in which IFNβ or GA exposure around the
time of conception was not associated with either lower
birth weight or gestational age [11].
The interest on paternally-mediated adverse pregnancy
outcomes comes from the notion that drug intake around
conception could cause reproductive toxicity. Three main
mechanisms have been described: non-genetic (due to the
presence of a drug in seminal fluid), genetic (gene muta-
tion or chromosomal abnormality), and epigenetic (effect
on gene expression, genomic imprinting, or DNA methy-
lation) [16,17]. The development of spermatozoa from
germ cells takes approximately 64 days, and a further 2–5
days are required for spermatozoa to pass through the
epididymis [16,18]. This period of intense cellular trans-
formation could be considered to be highly susceptible to
environmental insults, including drug exposure. There-
fore, in our study, we considered as exposed those preg-
nancies fathered by MS patients who were taking DMD at
conception or had discontinued DMD within 70 days
before conception.
Interferon beta and glatiramer acetate have shown no
mutagenic effects on in vitro studies [19,20]. To date, in-
formation on interferon beta and glatiramer acetate sem-
inal fluid concentration and epigenetic effect on
offspring after paternal exposure are lacking.
In the present study we examined 78 pregnancies fa-
thered by MS patients, 45 exposed to DMD therapy at
time of conception.
We found no significant differences in the risk of spon-
taneous abortion and malformations, mean gestational
age, frequency of cesarean delivery, birth weight and birth
length between DMD exposed and unexposed pregnan-
cies. Moreover, comparing data of exposed pregnancies
with incidence estimates inferred from the Italian general
population [13], we found no significant association be-
tween DMD exposure and risk of spontaneous abortion
and cesarean delivery.
Although we found no significant difference in preterm
delivery rates between exposed and unexposed pregnan-
cies, the proportion of pre-term delivery observed in the
exposed group (17.1%) was higher than expected, consid-
ering the estimates extrapolated from general population.
There were no significant differences in the risk of
maternal complications, among which partial placental
abruption, preeclampsia, threatened abortion, threatenedpreterm delivery, and a minor infection. However, the
considerable heterogeneity of the observed maternal
complications in our small study sample, does not allow
to draw definitive conclusions.
Eventually, in our study sample, data on possible de-
velopmental abnormalities are encouraging, because in a
median follow-up period of 1.8 years we only observed
the occurrence of mild speech disorders in a child in the
unexposed pregnancies group.
Some limitations have to be considered in the inter-
pretation of the study’s results. The study sample was
relatively small, and some data of patients' partner were
lacking (for instance maternal age at conception). More-
over, since the questionnaire collected very detailed com-
plex medical data directly for the fathers a recall bias
cannot be excluded. Furthermore, we had no information
on sexual habits, and we cannot infer the influence of
paternal exposure during pregnancy related to potential in
utero fetal exposure. Finally, as for the comparison of the
Italian population, demographic matching cannot be
warranted, since information on age of the mothers was
lacking.
Conclusions
Our data suggest the absence of association between pa-
ternal DMD exposure at time of conception and risk of
spontaneous abortion, adverse fetal outcomes and con-
genital malformations. Although we found a higher pre-
term delivery rate in the exposed group, these data should
be interpreted with caution in light of the above consider-
ations. Further studies addressing the issue of MS patients
paternity are desirable, to better clarify the role of DMD
fathers intake prior and during pregnancy and to supply
guidelines for clinical practice purposes.
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